Targeting more than tumors: The impact of enfortumab vedotin and pembrolizumab (EV/P) on skeletal muscle loss and sarcopenia in metastatic urothelial carcinoma (mUC).
Authors
Isabel Brinkmann
Alexander J. Tamalunas (ORCID: https://orcid.org/0000-0002-4659-2262)
Can Aydogdu (ORCID: https://orcid.org/0009-0003-1486-183X)
Melanie Götz
Elena Berg (ORCID: https://orcid.org/0000-0002-0090-796X)
Targeting more than tumors: The impact of enfortumab vedotin and pembrolizumab (EV/P) on skeletal muscle loss and sarcopenia in metastatic urothelial carcinoma (mUC).
Isabel Brinkmann, Alexander J. Tamalunas, Can Aydogdu, Melanie Götz et al.
Journal
Journal of Clinical Oncology
Topics
Cancer Diagnosis and Treatment
article
Targeting more than tumors: The impact of enfortumab vedotin and pembrolizumab (EV/P) on skeletal muscle loss and sarcopenia in metastatic urothelial carcinoma (mUC).
Isabel Brinkmann, Alexander J. Tamalunas, Can Aydogdu, Melanie Götz, Elena Berg, Frederik Kolligs, Susan Hahn, Jozefina Casuscelli, Benazir Enzinger, Christian Georg Stief, Marie Semmler
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(5_suppl)
Institutions
LMU Klinikum (DE), Ludwig-Maximilians-Universität München (DE)